ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Silexion Therapeutics Corporation

Silexion Therapeutics Corporation (SLXN)

1,90
-0,15
(-7,32%)
Fermé 02 Février 10:00PM
1,86
-0,04
(-2,11%)
Après les heures de négociation: 1:59AM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
1,86
Prix Achat
1,86
Prix Vente
1,88
Volume échangé
9 205 402
1,92 Fourchette du Jour 2,40
0,575 Plage de 52 semaines 41,85
Clôture Veille
2,05
Ouverture
2,18
Dernière Transaction
45
@
1.8605
Dernière heure de transaction
Volume moyen (3 m)
15 356 828
Volume financier
US$ 19 227 620
VWAP
2,0887

SLXN Dernières nouvelles

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave the company a Strong Buy Rating and a $9 Price...

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

KRAS, one of the most mutated oncogenes across cancers, drives aggressive and treatment-resistant tumors. Silexion’s latest data highlights SIL-204’s ability to enhance first-line therapies...

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Silexion Therapeutics (NASDAQ: SLXN) is advancing precision oncology with a focus on KRAS-driven cancers, among the most challenging targets in oncology. In collaboration with Evonik, Silexion...

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...

Silexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXN

December 11, 2024 -- InvestorsHub NewsWire -- via PESG Research -- The field of precision oncology has witnessed groundbreaking advancements in recent years, and Silexion Therapeutics (NASDAQ:...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
11.19177.6119402990.673.450.5751161530942.38082127CS
4-0.18-8.823529411762.043.450.575357502092.33628635CS
12-0.57-23.45679012352.434.230.575153568282.51609292CS
26-39.27-95.477753464641.1341.850.57589934343.32469067CS
52-39.27-95.477753464641.1341.850.57589934343.32469067CS
156-39.27-95.477753464641.1341.850.57589934343.32469067CS
260-39.27-95.477753464641.1341.850.57589934343.32469067CS

SLXN - Frequently Asked Questions (FAQ)

What is the current Silexion Therapeutics share price?
The current share price of Silexion Therapeutics is US$ 1,86
What is the 1 year trading range for Silexion Therapeutics share price?
Silexion Therapeutics has traded in the range of US$ 0,575 to US$ 41,85 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
731,1M
REBNReborn Coffee Inc
US$ 3,31
(63,05%)
55,54M
FCUVFocus Universal Inc
US$ 5,87
(56,62%)
1,73M
SOPASociety Pass Inc
US$ 1,54
(56,50%)
13,87M
CYCNCyclerion Therapeutics Inc
US$ 3,92
(54,33%)
82,57M
ENVBEnveric Biosciences Inc
US$ 2,0899
(-46,41%)
1,58M
NIVFNewGenIvf Group Ltd
US$ 0,1489
(-42,51%)
14,91M
GLSTGlobal Star Acquisition Inc
US$ 8,83
(-39,10%)
23,93k
PRPHProPhase Labs Inc
US$ 0,2633
(-38,02%)
900,48k
SPGCSacks Parente Golf Inc
US$ 0,5601
(-37,86%)
7,42M
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
731,1M
NVDANVIDIA Corporation
US$ 120,07
(-3,67%)
388,5M
RIMEAlgorhythm Holdings Inc
US$ 0,02565
(5,12%)
341,8M
CLEUChina Liberal Education Holdings Ltd
US$ 0,1938
(30,77%)
237,15M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0355
(-11,25%)
236,44M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock